IRIS Raises Several Hundred Million RMB in Series B+ Financing, with CEC Capital as Exclusive Financial Advisor

Recently, IRIS, a world-leading contact lens R&D and manufacturing platform, announced it has raised several hundred million RMB in Series B+ Financing. This round of financing was exclusively led by Cenova Capital, a well-known investment institution.

CEC Capital acted as the exclusive financial advisor to IRIS in this transaction.

The contact lens industry has the dual attributes of consumer goods and medical devices, with high barriers to production technology. Currently, more than 90% of brands in the market adopt OEM production. Among them, daily disposable products have become the mainstream of the global market and are in a stage of rapid growth due to their health and convenience. However, due to their extremely short wearing cycle, they have extremely high requirements in terms of material biocompatibility, lens forming accuracy and aseptic technology, resulting in more prominent technical difficulties and production challenges. For a long time, the Chinese mainland market has been dominated by overseas manufacturers. The commissioning of IRIS's independently developed intelligent contact lens factory marks the first time that a local Chinese brand has achieved independent iteration capabilities in core materials, process technology and production equipment, and has reached or even exceeded the standards of leading manufacturers in Europe, America, Japan, South Korea and Taiwan, China in many key technical indicators.